Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
News|Articles|May 31, 2024
Psychedelics Beyond Clinical Settings Poll
Author(s)Psychiatric Times Editors
Answer a quick question on psychedelics!
Advertisement
Have your patients shared or expressed interest in psychedelics for therapeutic purposes outside of clinical settings?
Advertisement
Related to this article
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Cannabis Use Prevalent In Substance-Related Adolescent Emergency Care: Insights From Kevin Xu, MD
2
Schizo-Obsessed! Untangling the Overlap Between Obsessive Compulsive Disorder and Schizophrenia
3
Promoting Literacy to Improve Child Development: Reading Model Boosts Efforts
4
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
5